<DOC>
	<DOCNO>NCT01713673</DOCNO>
	<brief_summary>Up 20 subject treat . Subjects receive two ( 2 ) bilateral Ultherapy™ Sham treatment axilla . The study hypothesis subject receive Ultherapy™ treatment great reduction axillary sweat compare subject receive Sham treatment . Follow-up visit occur 7 14 day follow treatment # 1 , 7 , 14 , 30 , 60 90 day follow treatment # 2 . At follow-up visit , assessment complete compare amount axillary sweating compare baseline .</brief_summary>
	<brief_title>Feasibility Study : Safety Efficacy Ulthera® System Treatment Axillary Hyperhidrosis</brief_title>
	<detailed_description>This study prospective , single-center , randomize , sham-controlled , blind pilot clinical trial . Subjects randomly assign one two treatment group 2:1 randomization scheme , two ( 2 ) subject assign receive Ultherapy™ treatment every one subject assign receive Sham treatment . Gravimetric measurement sweat production starch iodine test perform , Hyperhidrosis Disease Severity Scale ( HDSS ) score obtain , prior treatment follow-up visit . Patient satisfaction also assess . Sham treat subject option continue Stage II receive active treatment completion Stage I 90 day study visit . In protocol amendment , initial Stage I study cohort , exclude Sham treat subject opt continue Stage II , recruit complete one long-term follow-up visit 365 day follow subject ' second study treatment . The follow-up assessment complete compare amount axillary sweating compare baseline .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Male female , age 1875 Subject good health Diagnosis bilateral axillary hyperhidrosis refractory previous topical therapy At least 50 mg spontaneous rest axillary sweat production axilla measure gravimetrically room temperature/humidity period 5 minute A HDSS score 3 4 . An attempt make approximate equal number score 3 4 Understands accepts obligation undergo procedure area treat followup period Absence physical condition unacceptable investigator Willingness ability provide write informed consent HIPAA authorization prior performance studyrelated procedure Subjects childbearing potential must negative urine pregnancy test result must lactate Dermal disorder include infection anticipate treatment site either axilla Previous botulinum toxin treatment axilla past year Expected use botulinum toxin treatment disease study period Known allergy starch powder iodine Secondary hyperhidrosis , example , hyperhidrosis secondary underlying disease include hyperthyroidism , lymphoma malaria Previous surgical treatment hyperhidrosis include sympathectomy , surgical debulking sweat gland , subcutaneous tissue curettage ultrasonic surgery Unwillingness wash deodorant abstain use 72 hour prior treatment assessment History previous Ultherapy™ treatment axilla Subjects history bleed disorder Use cholinomimetics , anticholinergic , oral herbal medicine treatment hyperhidrosis Inability withhold use antiperspirant deodorant , topical treatment hyperhidrosis within 72 hour prior study treatment assessment Unwillingness complete shave removal underarm hair within 12 hour prior study treatment followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hyperhidrosis</keyword>
	<keyword>Axillary sweating</keyword>
	<keyword>Ulthera® System</keyword>
	<keyword>Ultherapy™ Treatment</keyword>
	<keyword>Ulthera , Inc .</keyword>
</DOC>